Published in Br J Clin Pharmacol on July 11, 2008
Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol (2010) 1.10
Extensive phlegmon and pyoderma gangrenosum: diagnostic difficulties. Postepy Dermatol Alergol (2015) 0.91
Development of pyoderma gangrenosum during therapy with infliximab. J Dermatol Case Rep (2009) 0.91
Looking back: editors' pick of 2008. Br J Clin Pharmacol (2009) 0.87
Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature. Clin Cosmet Investig Dermatol (2010) 0.75
Pathogenesis and clinical features of psoriasis. Lancet (2007) 5.01
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol (2008) 3.95
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol (2003) 3.28
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol (2007) 2.85
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 2.80
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.51
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol (2007) 2.26
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol (2008) 1.99
Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther (2005) 1.85
A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol (2003) 1.77
Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol (2004) 1.61
Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat (2007) 1.60
Treatment of psoriasis with adalimumab. Clin Exp Dermatol (2007) 1.48
Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum (2007) 1.44
Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol (2007) 1.44
Adalimumab: a review of side effects. Expert Opin Drug Saf (2005) 1.35
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol (2005) 1.32
Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol (2005) 1.31
Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol (2005) 1.31
Current and future management of psoriasis. Lancet (2007) 1.29
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol (2007) 1.28
The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis (2007) 1.23
Adalimumab: a new modality for Behçet's disease? Ann Rheum Dis (2006) 1.20
Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond) (2006) 1.07
The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol (2007) 1.06
Psoriatic arthritis. Dermatol Ther (2004) 1.01
Urticaria and angiedema-like skin reactions in a patient treated with adalimumab. Clin Rheumatol (2006) 1.00
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol (2007) 0.98
Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine. Clin Rheumatol (2007) 0.96
Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol (2007) 0.96
Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol (2007) 0.95
Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology. Curr Rheumatol Rep (2006) 0.93
Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol (2005) 0.93
Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis (2006) 0.92
Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds (2006) 0.90
Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol (2006) 0.90
Treatment of severe, recalcitrant, major aphthous stomatitis with adalimumab. Cutis (2005) 0.89
Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol (2006) 0.88
Multicentric reticulohistiocytosis responding to tumor necrosis factor-alpha inhibition in a renal transplant patient. J Rheumatol (2005) 0.87
The cutting edge. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol (2006) 0.85
Infectious complications of tumor necrosis factor-alpha antagonists. Int J Dermatol (2005) 0.84
TNF- alpha inhibitors. Dermatol Ther (2007) 0.81
Rapid response of IgA pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil. J Am Acad Dermatol (2005) 0.81
Refractory sweet syndrome with autoimmune organizing pneumonia treated with monoclonal antibodies to tumor necrosis factor. J Clin Rheumatol (2004) 0.80
Extensive plaque psoriasis successfully treated with adalimumab (Humira). Br J Dermatol (2005) 0.78
Adalimumab: in psoriatic arthritis. Drugs (2006) 0.76
Comma hairs: a dermatoscopic marker for tinea capitis: a rapid diagnostic method. J Am Acad Dermatol (2008) 1.62
New trichoscopy findings in trichotillomania: flame hairs, V-sign, hook hairs, hair powder, tulip hairs. Acta Derm Venereol (2014) 1.52
Trichoscopy in genetic hair shaft abnormalities. J Dermatol Case Rep (2008) 1.48
Dermoscopy as a tool for rapid diagnosis of monilethrix. J Drugs Dermatol (2007) 1.42
Trichoscopy of cicatricial alopecia. J Drugs Dermatol (2012) 1.41
Trichoscopy. Arch Dermatol (2008) 1.28
Dermoscopy for the pediatric dermatologist part I: dermoscopy of pediatric infectious and inflammatory skin lesions and hair disorders. Pediatr Dermatol (2013) 1.24
Dermoscopy in female androgenic alopecia: method standardization and diagnostic criteria. Int J Trichology (2009) 1.13
Alopecia areata incognita: true or false? J Am Acad Dermatol (2009) 1.07
Dermoscopic evaluation of nodular melanoma. JAMA Dermatol (2013) 0.99
Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol (2005) 0.97
New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol (2011) 0.96
Hair shaft videodermoscopy in netherton syndrome. Pediatr Dermatol (2009) 0.94
Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy. J Dermatol Case Rep (2010) 0.93
Cylindroma transforming into basal cell carcinoma in a patient with Brooke-Spiegler syndrome. J Dermatol Case Rep (2007) 0.90
Mycoplasma pneumoniae-induced pneumonia with Stevens-Johnson syndrome of acute atypical course. Pol Arch Med Wewn (2008) 0.89
Treatment of systemic lupus erythematosus with epratuzumab. Br J Clin Pharmacol (2011) 0.89
The 'PDA nail': traumatic nail dystrophy in habitual users of personal digital assistants. Am J Clin Dermatol (2009) 0.87
[The usefulness of high frequency ultrasonography in dermatological practice--ultrasound features of selected cutaneous lesions]. Pol Merkur Lekarski (2011) 0.83
Methods of hair loss evaluation in patients with endocrine disorders. Endokrynol Pol (2010) 0.81
[Psychiatric comorbidities of psoriasis: pilot study]. Psychiatr Pol (2010) 0.80
Briakinumab for the treatment of plaque psoriasis. BioDrugs (2012) 0.78
Unanswered questions in evaluating rituximab efficacy: comment on the article by Merrill et al. Arthritis Rheum (2010) 0.77
Criteria for diagnosing pemphigus vulgaris and pemphigus foliaceus by reflectance confocal microscopy. Skin Res Technol (2011) 0.77
Vulvovaginal-gingival Lichen Planus: Association with Lichen Planopilaris and Stratified Epithelium-specific Antinuclear Antibodies. Acta Derm Venereol (2016) 0.76
[Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment]. Pol Merkur Lekarski (2008) 0.75
[Methods of hair loss evaluation in patients with endocrine disorders]. Endokrynol Pol (2011) 0.75
Efficacy of Isotretinoin and Acitretin in Treatment of Frontal Fibrosing Alopecia: Retrospective Analysis of 54 Cases. J Drugs Dermatol (2017) 0.75
[Raynaud's disease and Raynaud's phenomenon in connective tissue diseases]. Pol Arch Med Wewn (2002) 0.75
Prolactin synthesis by lymphocytes from patients with systemic sclerosis. Biomed Pharmacother (2006) 0.75
[Current treatment of systemic sclerosis. Part I. Immunosuppressive treatment]. Pol Merkur Lekarski (2008) 0.75
Atopic and Non-atopic Eczema. Acta Dermatovenerol Croat (2016) 0.75
[Rituximab in systemic lupus erythematosus. Part II: review of clinical experience]. Pol Merkur Lekarski (2010) 0.75
The effect of parathyroid hormones on hair follicle physiology: implications for treatment of chemotherapy-induced alopecia. Skin Pharmacol Physiol (2015) 0.75
[Rituximab in systemic lupus erythematosus. Part I. Theoretical basis]. Pol Merkur Lekarski (2010) 0.75
[Systemic sclerosis--clinical course and treatment possibilities]. Przegl Lek (2005) 0.75